Navigation Links
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Date:1/6/2009

Program Expands on Successful Results from prior U.S., U.K. and China Trials

SAN DIEGO, Jan. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, today announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.

This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.

ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.

For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.

VTI Chairman and CE
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
2. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
3. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... NEW YORK , July 7, 2015 ... Lina Medical ApS has been settled for an undisclosed ... the case was filed in March 2014 in the ... , on behalf of a widower whose wife ... she had undergone a hysterectomy that involved the use ...
(Date:7/7/2015)... , July 7, 2015 According ... by Method (Manual, Automated), Product (Consumables, Instrument), Application (Aerobic, Anaerobic, ... Academic Research Institute) - Forecast to 2019", published by MarketsandMarkets, ... $3,893.5 Million by 2019 from $2,750.2 Million in 2014 at ... 1 78 ma rket ...
(Date:7/7/2015)... MILAN , July 7, 2015 /PRNewswire/ ... que la société P&R annonce l,acquisition de ... active au niveau mondial, spécialisée dans la ... à base d,acide hyaluronique.      ... est l,un des principaux groupes chimiques et ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... Nov. 20 PAREXEL International,Corporation (Nasdaq: ... bio/pharmaceutical services,organization, has appointed Dr. Victor ... Pharmacoepidemiology within the Company,s Clinical Research,Services ... clients in,the design and conduct of ...
... ANTIPOLIS, France, Nov. 20 NicOx S.A. (Eurolist:,COX) today ... in a phase 2 proof of concept study for ... TOPIGEN press release attached.,This new study is expected to ... COPD. TPI 1020 is a new chemical entity and ...
Cached Medicine Technology:PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 2PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 3PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 4NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 2NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 3NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 4NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 5NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 6NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 7
(Date:7/7/2015)... ... July 07, 2015 , ... Researchers at UC Davis have ... (or didn’t) and how similar programs can be improved. , Interviewing staff, clinicians ... Community of Practice (HEALTH COP) program, the team identified four factors that helped ...
(Date:7/7/2015)... ... July 07, 2015 , ... sweetFrog ... interact with fans and provide frozen yogurt offerings at Live Nation's amphitheaters in ... will be on site at concerts throughout the summer and brand ambassadors will ...
(Date:7/7/2015)... BELLINGHAM, WA (PRWEB) , ... July 07, 2015 , ... ... set to break ground as early as Summer 2015 on a four-acre site in ... dollar project, with the support of city officials and other members of the local ...
(Date:7/7/2015)... ... July 07, 2015 , ... The ... a mark on the cosmetic surgery industry with its commitment, teamwork, and dedication ... VisitandCare.com partnered medical provider is committed to patient safety, world-class results, and compassionate ...
(Date:7/7/2015)... ... 2015 , ... Owners of Green Ladies Cleaning are very pleased to announce ... This honor can only be gained by votes from Madison Magazine readership. , The ... and methods they use daily. Having a home cleaned with all-natural products means that ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 2Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 3Health News:sweetFrog Mobile Trucks to Offer Froyo at Live Nation Venues 2Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 2Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 3Health News:Environmentally-Friendly House Cleaning Company Wins Best of Madison Magazine Award 2
... ... based scrubs manufacturer, has posted their client ratings to their website. , ... Austin, TX (PRWEB) September 16, 2009 -- The ... ratings to their website. "Ratings help potential clients make decisions on what they want ...
... Five ... special recognition in ,The Best Lawyers in America®, annual peer-review publication. , ... Cleveland, OH (PRWEB) September 16, 2009 -- The ... Spangenberg, Shibley & Liber Ohio Law Firm as among the nation,s top lawyers. ...
... Sept. 16 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management ... September 16, 2009, at 10:30 AM Eastern. , , ... Hotel in New York. , The conference will be webcast ... can be accessed at www.celltherapeutics.com . , ...
... Calif., Sept. 16 The International Sports Sciences Association ... magazine as a Military Friendly School for 2010, placing them in ... The only fitness organization to be listed as a Nationally ... the International Sports Sciences Association (ISSA) has been approved for Military ...
... , NEW YORK, Sept. 15 The ... Jewish groups in the United States who are concerned about the ... plan to protest outside the hospital,s Manhattan office at 50 W. 58th ... The woman,s child, now three and a half years of age, ...
... Lower Rates ... Reform , ... September 15, 2009 -- A recent study released by John Hopkins University and ... (MA) plans score better than traditional Medicare fee-for-service (FFS) plans in key quality criteria. As ...
Cached Medicine News:Health News:Clients Post 5-Star Product Reviews at blue sky scrubs 2Health News:Clients Post 5-Star Product Reviews at blue sky scrubs 3Health News:Clients Post 5-Star Product Reviews at blue sky scrubs 4Health News:Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 2Health News:Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 3Health News:ISSA Recognized as Military Friendly School 2Health News:American Jews to Protest Against Hadassah Hospital 2Health News:Study Cites Medicare Advantage Plans Outperform Medicare Fee-For-Service Plans 2Health News:Study Cites Medicare Advantage Plans Outperform Medicare Fee-For-Service Plans 3